68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer. (November 2021)

• Record Type: Journal Article
• Authors: Fu, Hao; Fu, Jie; Huang, Jingxiong; Pang, Yizhen; Chen, Haojun
• Is Part Of: Clinical nuclear medicine. Volume 46:Number 11(2021)
• Publication Date: 2021-11
• Subjects: 18F-FDG -- 68Ga-FAPI -- PET/CT -- radioiodine-refractory -- differentiated thyroid cancer; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003730
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: 18 F-FDG PET/CT is a useful imaging modality for detecting disease recurrence and metastases in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). However, the sensitivity of 18 F-FDG PET/CT in RAIR-DTC is not very satisfactory. 68 Ga-FAPI is a promising PET tracer that allowed imaging of various types of cancer. In this case, 68 Ga-FAPI showed a far better signal-to-background ratio than 18 F-FDG for detecting the RAIR-DTC metastatic lesions, especially for detecting the small pulmonary metastases. Therefore, 68 Ga-FAPI may be a promising alternative to 18 F-FDG for detecting tumor recurrence and metastases in RAIR-DTC. It could also be used for guiding FAP-targeted radionuclide therapy.